Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 381

1.

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E.

N Engl J Med. 2004 Jul 22;351(4):337-45.

PMID:
15269313
[PubMed - indexed for MEDLINE]
Free Article
2.

Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.

Kang MJ, Hong YS, Kim KP, Kim SY, Baek JY, Ryu MH, Lee JL, Chang HM, Kim MJ, Chang HJ, Kang YK, Kim TW.

Invest New Drugs. 2012 Aug;30(4):1607-13. doi: 10.1007/s10637-011-9703-8. Epub 2011 Jun 25.

PMID:
21706149
[PubMed - indexed for MEDLINE]
3.

Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial.

Vincenzi B, Santini D, Rabitti C, Coppola R, Beomonte Zobel B, Trodella L, Tonini G.

Br J Cancer. 2006 Mar 27;94(6):792-7.

PMID:
16508634
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience.

Gebbia V, Del Prete S, Borsellino N, Ferraù F, Tralongo P, Verderame F, Leonardi V, Capasso E, Maiello E, Bordonaro R, Stinco S, Agostara B, Barone C.

Clin Colorectal Cancer. 2006 Mar;5(6):422-8.

PMID:
16635281
[PubMed - indexed for MEDLINE]
5.

Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.

Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, Kemeny NE, Hollywood EM, Gonen M, Quinones M, Morse M, Chen HX.

J Clin Oncol. 2007 Oct 10;25(29):4557-61. Epub 2007 Sep 17.

PMID:
17876013
[PubMed - indexed for MEDLINE]
Free Article
6.

Integration of novel agents in the treatment of colorectal cancer.

Iqbal S, Lenz HJ.

Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S32-9. Review.

PMID:
15309512
[PubMed - indexed for MEDLINE]
7.

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL.

N Engl J Med. 2000 Sep 28;343(13):905-14.

PMID:
11006366
[PubMed - indexed for MEDLINE]
Free Article
8.

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kröning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris HA 3rd.

J Clin Oncol. 2008 May 10;26(14):2311-9. doi: 10.1200/JCO.2007.13.1193. Epub 2008 Apr 7.

PMID:
18390971
[PubMed - indexed for MEDLINE]
Free Article
9.

Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.

Jean GW, Shah SR.

Pharmacotherapy. 2008 Jun;28(6):742-54. doi: 10.1592/phco.28.6.742. Review.

PMID:
18503402
[PubMed - indexed for MEDLINE]
10.

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P.

N Engl J Med. 2009 Apr 2;360(14):1408-17. doi: 10.1056/NEJMoa0805019.

PMID:
19339720
[PubMed - indexed for MEDLINE]
Free Article
11.

Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.

Raoul JL, Van Laethem JL, Peeters M, Brezault C, Husseini F, Cals L, Nippgen J, Loos AH, Rougier P.

BMC Cancer. 2009 Apr 14;9:112. doi: 10.1186/1471-2407-9-112.

PMID:
19366444
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer.

Personeni N, Hendlisz A, Gallez J, Galdon MG, Larsimont D, Van Laethem JL, Nagy N, Barette M, Paesmans M, Cardoso F, Bleiberg H.

Semin Oncol. 2005 Dec;32(6 Suppl 9):S59-62.

PMID:
16399434
[PubMed - indexed for MEDLINE]
13.

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

Tappenden P, Jones R, Paisley S, Carroll C.

Health Technol Assess. 2007 Mar;11(12):1-128, iii-iv. Review.

PMID:
17346499
[PubMed - indexed for MEDLINE]
Free Article
14.

Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin.

Han HS, Chang HJ, Hong YS, Kim SY, Lee KS, Jung KH.

Dis Colon Rectum. 2009 Jun;52(6):1144-51; discussion 1152-3. doi: 10.1007/DCR.0b013e31819edbf9.

PMID:
19581859
[PubMed - indexed for MEDLINE]
15.

Assessment of baseline clinical predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer.

Hebbar M, Di Fioré F, Conroy T, Giraud C, Gasnault L, Fournier C, Péreira R, Bouché O, Fournier P, Deligny N, Joly JP, Maes P, Rad E, Michel P, Adenis A.

Oncology. 2007;73(3-4):185-91. doi: 10.1159/000127385. Epub 2008 Apr 16.

PMID:
18418011
[PubMed - indexed for MEDLINE]
16.

Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines.

Tahara M, Shirao K, Boku N, Yamaguchi K, Komatsu Y, Inaba Y, Arai T, Mizunuma N, Satoh T, Takiuchi H, Nishina T, Sakata Y.

Jpn J Clin Oncol. 2008 Nov;38(11):762-9. doi: 10.1093/jjco/hyn102. Epub 2008 Oct 4.

PMID:
18836202
[PubMed - indexed for MEDLINE]
Free Article
17.

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P.

Lancet. 2000 Mar 25;355(9209):1041-7. Erratum in: Lancet 2000 Apr 15;355(9212):1372.

PMID:
10744089
[PubMed - indexed for MEDLINE]
18.

Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.

García-Foncillas J, Díaz-Rubio E.

Clin Transl Oncol. 2010 Aug;12(8):533-42. doi: 10.1007/s12094-010-0551-3. Review.

PMID:
20709651
[PubMed - indexed for MEDLINE]
19.

Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.

Scartozzi M, Bearzi I, Pierantoni C, Mandolesi A, Loupakis F, Zaniboni A, Catalano V, Quadri A, Zorzi F, Berardi R, Biscotti T, Labianca R, Falcone A, Cascinu S.

J Clin Oncol. 2007 Sep 1;25(25):3930-5.

PMID:
17761976
[PubMed - indexed for MEDLINE]
Free Article
20.

Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.

Shitara K, Yuki S, Yoshida M, Takahari D, Utsunomiya S, Yokota T, Sato Y, Inaba Y, Tajika M, Kawai H, Yamaura H, Kato M, Yamazaki K, Komatsu Y, Muro K.

Invest New Drugs. 2012 Apr;30(2):787-93. doi: 10.1007/s10637-010-9615-z. Epub 2010 Dec 22.

PMID:
21174225
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk